Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy
Cancer · 2025
DOI: 10.1002/cncr.35552 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer, 2025. Verfasst von Miguel Arguello-Tomas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However, some patients require intervention shortly after diagnosis. In the past decade, several risk scores (RS) have been developed to predict disease progression, yet some patients are misclassified. On the other hand, IGHV subset 2 (IGHV2) predicts poor outcomes.
Methods
A retrospective and multicentric study was conducted to compare the accuracy of five different RS (IPS‐E, CR0, AIPS‐E, CLL‐IPI, and Barcelona‐Brno) to predict disease progression in 781 stage A previously untreated patients with CLL. As an exploratory analysis, it was further investigated whether the inclusion of the IGHV2 as a poor prognostic parameter improved the accuracy of RS.
Results
All the scores identified a similar group of patients with CLL in early stage with low‐, intermediate‐, and high‐risk progression. Discrimination was high and similar in all RS (c‐index = 0.74–0.79, area under the curve = 0.7–0.75), as well as calibration ( p = .98) and parsimony, although CLL‐IPI showed the best results (Akaike information criterion = 441). A total of 34.4% of patients were categorized within the same RS and concordance was at least moderate between RS.
Conclusion
Moreover, the results suggest that IGHV2 may improve the accuracy of RS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
- Facultat Medicina Universitat Autònoma Barcelona, Barcelona, Spain.
- Institut de Recerca Sant Pau, Barcelona, Spain.
- Institut Josep Carreras, Barcelona, Spain.
- Hospital Clínic Barcelona, Barcelona, Spain.
- Institut Investigaciones Biomédicas August Pi i Sunyer, Barcelona, Spain.
ORCID-Profile: Miguel Arguello-Tomas, Pablo Mozas, Nil Albiol
Zitieren
APA
Arguello-Tomas, M., Mozas, P., Albiol, N., López-Esteban, M., Sierra, J., Nomdedéu, J., Martinez-Laperche, C., Moga, E., Piñeyroa, J. A., Delgado, J., Osorio, S., & Moreno, C. (2025). Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy. Cancer. https://doi.org/10.1002/cncr.35552
Vancouver
Arguello-Tomas M, Mozas P, Albiol N, López-Esteban M, Sierra J, Nomdedéu J, et al. Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy. Cancer. 2025. doi:10.1002/cncr.35552
BibTeX
@article{ArguelloTomas2025,
author = {Arguello-Tomas, Miguel and Mozas, Pablo and Albiol, Nil and López-Esteban, Miguel and Sierra, Jorge and Nomdedéu, Josep and Martinez-Laperche, Carolina and Moga, Esther and Piñeyroa, Juan A and Delgado, Julio and Osorio, Santiago and Moreno, Carol},
title = {Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35552}
}
EUVIMED